**Appendix Table D21. Reduction in migraine days and duration with selective calcium channel blocker nimodipine vs. placebo (results from low risk of bias randomized controlled clinical trial)3**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Dose** | **Definition of outcome** | **Mean [SD) with drug** | **Mean [SD) with placebo** | **Mean difference (95% CI)** | **Cohen standardized mean difference**  **(95% CI)** | **Means ratio**  **(95% CI)** |
| 10 to 20mg three times daily (<40kg to 10mg=5 drops TIS to 40-50 kg to 16mg=8 drops TID to >50kg to 20mg=10 drops TID) | Frequency of headache attacks/month | 2.8 [0.6] | 1.9 [0.7] | **0.9 (0.5 to 1.3)** | **1.38 (0.66 to 2.10)** | **1.47 (1.22 to 1.79)** |
| Duration to number of hours/attacks | 5.0 [1.2] | 4.4 [1.1] | 0.6 (-0.1 to 1.3) | 0.52 (-0.13 to1.18) | 1.14 (0.97 to 1.33) |

Bold - significant differences at 95% confidence level when 95% CI of mean difference do not include 0; SD = standard deviation